Alamar Biosciences adds Robert Ragusa to board

Alamar Biosciences, Inc. (ALMR) reported that its board of directors appointed Robert Ragusa to the board effective September 1, 2026.

Rhea-AI Filing Summary

Alamar Biosciences, Inc. (ALMR) reported that its board of directors appointed Robert Ragusa to the board effective September 1, 2026. He will serve as a Class I Director with an initial term expiring at the company’s 2027 Annual Meeting of Stockholders.

Ragusa was also appointed to the board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. He will receive compensation under the company’s Non-Employee Director Compensation Policy and will enter into its standard indemnification agreement. The company states there were no arrangements leading to his selection and no related person transactions requiring disclosure.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Appointment date: August 28, 2026 Effective date: September 1, 2026 Term expiry: 2027 Annual Meeting of Stockholders

3 metrics

Appointment date August 28, 2026 Date the board appointed Robert Ragusa as director

Effective date September 1, 2026 Date Robert Ragusa’s board appointment becomes effective

Term expiry 2027 Annual Meeting of Stockholders End of initial term as Class I Director

Key Terms

Emerging growth company, Non-Employee Director Compensation Policy, indemnification agreement, related person transactions

4 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Non-Employee Director Compensation Policy financial

"under the terms of the Company’s Non-Employee Director Compensation Policy"

indemnification agreement regulatory

"Mr. Ragusa will enter into the Company’s standard form of indemnification agreement"

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

related person transactions regulatory

"there are no related person transactions within the meaning of Item 404(a)"

Transactions between a company and individuals or entities that have close relationships to the company’s insiders or major owners, such as executives, directors, their family members, or firms they control. These deals matter to investors because they can affect the company's finances or fairness—like a shop owner buying supplies from a relative’s business, which could be normal but might also favor the relative or mask conflicts of interest—so transparency and terms are closely watched.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did Alamar Biosciences (ALMR) announce on August 28, 2026?

Alamar Biosciences announced that Robert Ragusa was appointed to its board of directors on August 28, 2026, with the appointment effective September 1, 2026. He will serve as a Class I Director with an initial term expiring at the 2027 Annual Meeting of Stockholders.

What committees will Robert Ragusa serve on at Alamar Biosciences (ALMR)?

Robert Ragusa was appointed to Alamar Biosciences’ Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, giving him roles across the company’s key oversight and governance committees as part of his board service.

How will Robert Ragusa be compensated as a director of Alamar Biosciences (ALMR)?

Robert Ragusa will be compensated under Alamar Biosciences’ Non-Employee Director Compensation Policy, which is described in the company’s final prospectus filed with the SEC on April 17, 2026. The filing does not restate the specific compensation amounts or structure.

When does Robert Ragusa’s initial term on the Alamar Biosciences (ALMR) board end?

Robert Ragusa will serve as a Class I Director with an initial term expiring at Alamar Biosciences’ 2027 Annual Meeting of Stockholders. His future service beyond that would depend on renomination and stockholder approval at that meeting.

Did Alamar Biosciences (ALMR) disclose any related person transactions with Robert Ragusa?

Alamar Biosciences stated there are no related person transactions with Robert Ragusa that are required to be disclosed under Item 404(a) of Regulation S-K, and that there were no arrangements or understandings with other persons pursuant to which he was selected.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:02 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:01 PM EDT Learn about SEC filing dates

false 0002104204 0002104204 2026-08-28 2026-08-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2026

Alamar Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-43235		36-4899036
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

47071 Bayside Parkway

Fremont, California 94538

(Address of principal executive offices, including zip code)

(510) 626-9888

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		ALMR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 28, 2026, the board of directors (the “Board”) of Alamar Biosciences, Inc. (the “Company”) appointed Robert Ragusa to the Board, effective as of September 1, 2026. Mr. Ragusa will serve as a Class I Director, with an initial term expiring at the Company’s 2027 Annual Meeting of Stockholders. Mr. Ragusa was also appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee of the Board.

Mr. Ragusa will be compensated as a member of the Board under the terms of the Company’s Non-Employee Director Compensation Policy substantially as described in the Company’s final prospectus filed with the U.S. Securities and Exchange Commission on April 17, 2026.

Mr. Ragusa will enter into the Company’s standard form of indemnification agreement. There were no arrangements or understandings between Mr. Ragusa and any other persons pursuant to which he was selected as a director, and there are no related person transactions within the meaning of Item 404(a) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission between Mr. Ragusa and the Company required to be disclosed herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 1, 2026				Alamar Biosciences, Inc.
				By:		/s/ Justin McAnear
						Justin McAnear
						Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB